177 related articles for article (PubMed ID: 20356977)
21. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of fatty acid synthase for lung cancer treatment.
Orita H; Coulter J; Lemmon C; Tully E; Vadlamudi A; Medghalchi SM; Kuhajda FP; Gabrielson E
Clin Cancer Res; 2007 Dec; 13(23):7139-45. PubMed ID: 18056164
[TBL] [Abstract][Full Text] [Related]
23. Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines.
Slade RF; Hunt DA; Pochet MM; Venema VJ; Hennigar RA
Anticancer Res; 2003; 23(2B):1235-43. PubMed ID: 12820377
[TBL] [Abstract][Full Text] [Related]
24. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells.
Zhou W; Tu Y; Simpson PJ; Kuhajda FP
Oncogene; 2009 Aug; 28(33):2979-87. PubMed ID: 19543323
[TBL] [Abstract][Full Text] [Related]
25. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.
Furuta E; Pai SK; Zhan R; Bandyopadhyay S; Watabe M; Mo YY; Hirota S; Hosobe S; Tsukada T; Miura K; Kamada S; Saito K; Iiizumi M; Liu W; Ericsson J; Watabe K
Cancer Res; 2008 Feb; 68(4):1003-11. PubMed ID: 18281474
[TBL] [Abstract][Full Text] [Related]
26. A new targeting approach for breast cancer gene therapy using the human fatty acid synthase promoter.
Yan C; Wen-Chao L; Hong-Yan Q; Rui Z; Wei-Lin J; Hua H
Acta Oncol; 2007; 46(6):773-81. PubMed ID: 17653900
[TBL] [Abstract][Full Text] [Related]
27. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells.
Yoon MJ; Kim EH; Lim JH; Kwon TK; Choi KS
Free Radic Biol Med; 2010 Mar; 48(5):713-26. PubMed ID: 20036734
[TBL] [Abstract][Full Text] [Related]
28. Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects.
Yeh CW; Chen WJ; Chiang CT; Lin-Shiau SY; Lin JK
Pharmacogenomics J; 2003; 3(5):267-76. PubMed ID: 12931129
[TBL] [Abstract][Full Text] [Related]
29. Fatty acid synthase: a metabolic oncogene in prostate cancer?
Baron A; Migita T; Tang D; Loda M
J Cell Biochem; 2004 Jan; 91(1):47-53. PubMed ID: 14689581
[TBL] [Abstract][Full Text] [Related]
30. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
[TBL] [Abstract][Full Text] [Related]
31. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells.
Pacher M; Seewald MJ; Mikula M; Oehler S; Mogg M; Vinatzer U; Eger A; Schweifer N; Varecka R; Sommergruber W; Mikulits W; Schreiber M
Carcinogenesis; 2007 Jan; 28(1):49-59. PubMed ID: 16774935
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells.
Agostini M; Silva SD; Zecchin KG; Coletta RD; Jorge J; Loda M; Graner E
Oral Oncol; 2004 Aug; 40(7):728-35. PubMed ID: 15172643
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
34. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells.
Liu B; Wang Y; Fillgrove KL; Anderson VE
Cancer Chemother Pharmacol; 2002 Mar; 49(3):187-93. PubMed ID: 11935210
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.
Zhou W; Simpson PJ; McFadden JM; Townsend CA; Medghalchi SM; Vadlamudi A; Pinn ML; Ronnett GV; Kuhajda FP
Cancer Res; 2003 Nov; 63(21):7330-7. PubMed ID: 14612531
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition of triclosan to fatty acid synthase from goose uropygial glands and human breast cancer cells in vitro].
Wang YQ; Lai BS; Anderson VE
Ai Zheng; 2003 Mar; 22(3):270-3. PubMed ID: 12654184
[TBL] [Abstract][Full Text] [Related]
37. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
38. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
Sylvester PW; Shah S
Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
[TBL] [Abstract][Full Text] [Related]
39. Fatty acid synthase activity in tumor cells.
Little JL; Kridel SJ
Subcell Biochem; 2008; 49():169-94. PubMed ID: 18751912
[TBL] [Abstract][Full Text] [Related]
40. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma.
Milgraum LZ; Witters LA; Pasternack GR; Kuhajda FP
Clin Cancer Res; 1997 Nov; 3(11):2115-20. PubMed ID: 9815604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
